-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Aggressive B-Cell Lymphomas: Experts Discuss New Care Standards and Evolving Treatment Strategies

Sponsor: educational grants from Bristol Myers Squibb, Genmab US, Inc. and AbbVie, Karyopharm Therapeutics Inc., and Regeneron Pharmaceuticals, Inc. Provided by Clinical Care Options, LLC.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Clinical Practice (Health Services and Quality), Clinical Research, Combination therapy, drug development, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Technology and Procedures, Study Population, molecular testing, Pathology
Friday, December 9, 2022: 3:00 PM-6:00 PM
Napoleon B (Sheraton New Orleans)
John P. Leonard, MD, Weill Cornell Medicine and New York Presbyterian Hospital
Leonard: AbbVie: Consultancy; Astellas: Consultancy; AstraZeneca: Consultancy; Bayer: Consultancy; Beigene: Consultancy; Bristol-Myers Squibb: Consultancy; Calithera: Consultancy; Constellation: Consultancy; Eisai: Consultancy; Epizyme: Consultancy; Roche/Genentech: Consultancy; Genmab: Consultancy; Gilead/Kite: Consultancy; Grail: Consultancy; Incyte: Consultancy; Janssen: Consultancy; Karyopharm: Consultancy; Lilly: Consultancy; MEI Pharma: Consultancy; Merck: Consultancy; Mustang Bio: Consultancy; Novartis: Consultancy; Pfizer: Consultancy; Seattle Genetics: Consultancy; Second Genome: Consultancy; Sutro: Consultancy; ADC Therapeutics: Consultancy; BMS/Celgene: Consultancy; Regeneron: Consultancy; Miltenyi: Consultancy.
John N. Allan, Weill Cornell Medicine/New York Presbyterian Hospital and Laurie H. Sehn, MD, MPH, BC Cancer Centre for Lymphoid Cancer and The University of British Columbia
Allan: AbbVie: Consultancy, Honoraria, Speakers Bureau; Janssen: Honoraria, Research Funding, Speakers Bureau; AstraZeneca: Consultancy, Honoraria, Research Funding, Speakers Bureau; Genentech: Consultancy, Research Funding; PCYC: Consultancy, Speakers Bureau; BeiGene: Consultancy, Speakers Bureau; TG Therapeutics: Consultancy, Research Funding; Epizyme: Consultancy; ADC Therapeutics: Consultancy; Ascentage: Consultancy; Celgene: Research Funding. Sehn: Teva, Roche/Genentech: Consultancy, Honoraria, Research Funding; AbbVie, Acerta, Amgen, Apobiologix, AstraZeneca, BMS/Celgene, Debiopharm, Genmab, Gilead, Incyte, Janssen, Kite, Karyopharm, Lundbeck, Merck, Morphosys, Novartis, Sandoz, Seattle Genetics, Servier, Takeda, TG Therapeutics, Verastem: Consultancy; AbbVie, Acerta, Amgen, Apobiologix, AstraZeneca, BMS/Celgene, Gilead, Incyte, Janssen, Kite, Karyopharm, Lundbeck, Merck, Morphosys, Sandoz, Seattle Genetics, Servier, Takeda, TG Therapeutics, Verastem: Honoraria; Chugai: Consultancy, Honoraria.
On Demand program will be available here 1 month after the ASH meeting.

Attendees of this aggressive B-cell lymphoma symposium are invited to engage and interact with a panel of experts as they discuss the evolving treatment landscape for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) and how they are integrating state-of-the-art management approaches in their own clinical practice. The expert panel will discuss current clinical questions using available evidence, provide their answers to challenges affecting therapeutic decisions, and highlight emerging treatment options from new classes of agents in DLBCL and MCL. Presenters will review challenging patient cases while attendees vote on these cases and compare their answers with experts. Attendees can text questions directly to the panel for discussion throughout the symposium. Topics for discussion:

  • Timeline of approvals and discoveries for DLBCL and MCL
  • Patient selection and sequencing of new and emerging agents within the patient care continuum
  • Differentiating between novel and currently approved classes of agents and among agents within each class
  • Integrating precision medicine approaches into the current algorithm for induction, consolidation, and maintenance therapy
  • Key considerations for clinical application of new data and agents into practice or clinical trial enrollment
  • 2023 treatment algorithms for DLBCL and MCL